Medications

Real-world data links rosuvastatin to adverse effects on kidneys

Rosuvastatin is associated with increased risks for hematuria, proteinuria, and kidney failure with replacement therapy (KFRT) compared with atorvastatin use, according to a study published online July 19 in the Journal of ...

Cardiology

LDL reduction in hypertriglyceridemia varies per statin

(HealthDay)—For patients with hypertriglyceridemia, low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) reductions depend of the choice and dose of statin, according to research published in the May 1 issue ...

Cardiology

Atorvastatin/Ezetimibe beats atorvastatin after PCI

(HealthDay)—For Japanese patients who have undergone percutaneous coronary intervention (PCI), atorvastatin plus ezetimibe is associated with improved outcomes versus atorvastatin alone, according to a study published in ...

page 1 from 4

Atorvastatin

Atorvastatin (INN) ( /əˌtɔrvəˈstætən/), sold by Pfizer under the trade name Lipitor, is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.

Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2008 sales of US$12.4 billion, Lipitor was the top-selling branded pharmaceutical in the world. U.S. patent protection was scheduled to expire in June 2011. However, Pfizer made an agreement with Ranbaxy Laboratories to delay the generic launch in the U.S. until November 30, 2011.

This text uses material from Wikipedia, licensed under CC BY-SA